Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply

This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens Arcus Biosciences, Inc. (NYSE: RCUS ), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune d...